Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)
Saved in:
| Published in: | Rheumatology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301677600604162 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Rheumatology and Therapy |
| description | |
| discipline_display | Rheumatology |
| discipline_facet | Rheumatology |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:58290 |
| institution | FRELIP |
| journal_source_facet | Rheumatology and Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) Rheumatology General Rheumatology |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Rheumatology General Rheumatology Rheumatology General Rheumatology |
| subject_facet | Rheumatology General Rheumatology |
| title | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_auth | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_full | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_fullStr | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_full_unstemmed | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_short | Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials) |
| title_sort | olokizumab improves patient-reported outcomes in patients with active rheumatoid arthritis up to 106 weeks (results from the open-label extension of phase iii randomized clinical trials) |
| topic | Rheumatology General Rheumatology |
| url | https://link.springer.com/article/10.1007/s40744-026-00852-3 |